evolocumab,alirocumab
amgen,sanofi,regeneron
['fourier', 'odyssey']
 no. not necessarily. guideline 1st goal is &gt;50% reduction from baseline. if ascvd and ldl-c 50, demonstrates atherogenesis for that person. and agree that cells require some cholesterol. data from fourier and odyssey: ldl-c 29-33 mg/dl. n=500 &lt;20mg/dl - no ae/sae #acc23
Associate Prof @intermountain; @rmuohp; Pres @apac_Cardiology. follow/favorite ≠ endorse. Tweets, my view. #PAsInCardiology #PAtientsHealthFirst - on Spoutible